Evidence map›Paper›PMID 41524998›Full record

SynthesisCardiovascular toxicology2026

Ferric Carboxymaltose Among Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Controlled Trials.

Ahmed Elmorsy Mohamed, Ahmed Farid Gadelmawla, Zeyad Kholeif, Elsayed Balbaa, Ameer Awashra, Mohamed Elnady, Ahmed Diaa, Mohab Elnashar, Haytham A M Dwaik, Eman Mohyeldin and 5 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Cardiovascular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ahmed Elmorsy Mohamed *Faculty of Medicine, Tanta University, Tanta, Egypt.
Ahmed Farid Gadelmawla *Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Zeyad KholeifDepartment of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX, USA.
Elsayed BalbaaFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Ameer AwashraDepartment of Medicine, An Najah National University, Nablus, Palestine. Ameer.awashra7@gmail.com.
Mohamed ElnadyFaculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
Ahmed DiaaFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohab ElnasharDepartment of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Haytham A M DwaikFaculty of Medicine, University of Jordan, Amman, Jordan.
Eman MohyeldinFaculty of Medicine, Menoufia University, Menoufia, Egypt.
Ranem AfifyFaculty of Medicine, Tanta University, Tanta, Egypt.
Rana RashwanDepartment of Internal Medicine, NYC Health and Hospitals/Lincoln, Bronx, NY, USA.
Imad TahhanDepartment of Internal Medicine, Wellington Regional Medical Center, Wellington, FL, USA.
Khaled AliRosalind Franklin University of Medicine and Science, Chicago, IL, USA.
Islam Y ElgendyDivision of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency is common in heart failure and contributes to reduced exercise tolerance and worse outcomes. Ferric carboxymaltose offers targeted iron repletion, yet randomized trials have shown mixed results. This meta-analysis updates the evidence on its efficacy and safety in patients with heart failure and iron deficiency. Electronic databases were searched through December 2025 for RCTs that compared clinical outcomes with ferric carboxymaltose (FCM) versus control. The primary outcome was the composite heart failure hospitalization (HFH) or cardiovascular mortality. Summary estimates were constructed using a random effects model. Nine randomized clinical trials with 6,405 patients were included. FCM administration was associated with a lower incidence of composite HFH or cardiovascular mortality compared with the control group (risk ratio [RR] 0.86, 95% confidence interval [CI] 0.77 to 0.97, P = 0.014). There was a trend towards a lower incidence of HFH (RR 0.84, 95% CI 0.69 to 1.02, P = 0.07). There was no difference in the incidence of cardiovascular mortality (RR 0.88, 95% CI 0.75 to 1.03, P = 0.1) and all-cause mortality (RR 0.95, 95% CI 0.85 to 1.06, P = 0.38). FCM was associated with improvement in the 6MWT, with no significant change in KCCQ. Among patients with HF and iron deficiency, FCM was associated with a small but statistically significant lower incidence of HFH or cardiovascular mortality.

Indexed as

Anemia, Iron-DeficiencyFerric CompoundsHeart FailureHematinicsMaltoseAgedBiomarkersFemaleHospitalizationHumansIncidenceMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsBiomarkersferric carboxymaltoseFerric CompoundsHematinicsMaltoseFerric carboxymaltoseHeart failureIntravenous ironIron deficiency

Identifiers

PMID41524998

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.